Feature | January 05, 2015

Large-Scale Inferior Vena Cava Filters Study Examines Safety and Effectiveness of These Devices

Seven filter manufacturers participate in PRESERVE study

Vena Cava Filters, Embolic protection, Pulmonary Embolism, Venous Therapies

Image courtesy of Society of Vascular Surgery

January 5, 2015 — The first large-scale, multispecialty prospective clinical research trial to evaluate the use of inferior vena cava (IVC) filters and related follow-up treatment in the United States — initiated by a collaboration between the Society of Interventional Radiology (SIR) and the Society for Vascular Surgery (SVS) — is set to enroll the first patient in spring 2015 with participation from seven filter manufacturers.

Predicting the Safety and Effectiveness of Inferior Vena Cava Filters (PRESERVE) will directly address an August 2010 U.S. Food and Drug Administration (FDA) medical alert detailing the possibility that retrievable IVC filters could move or break, potentially causing significant health risks for patients. SVS and SIR collaboratively formed the IVC Filter Study Group Foundation, a 501(c)(3) nonprofit entity that sponsors and oversees PRESERVE. The study will have the goal of obtaining a real worldview of the safety and effectiveness of most filters placed in the United States.

 “The PRESERVE study will benefit patients by helping determine how well filters prevent pulmonary embolism and when retrievable filters should be removed,” noted Peter Lawrence, M.D., foundation vice president.

"Patient safety is imperative, which is why interventional radiologists and vascular surgeons are working together collaboratively to respond to FDA's concerns regarding filter safety and effectiveness," said John Kaufman, M.D., FSIR, foundation president.

Filter manufacturers are providing financial support to the IVC Filter Study Group Foundation to sponsor the PRESERVE study. The manufacturers and devices that will be included in the study are ALN Implants Chirurgicaux (ALN Vena Cava Filters); Argon Medical Devices Inc. (Option Elite Retrievable Vena Cava Filter designed and manufactured by Rex Medical); B. Braun Interventional Systems Inc. (VenaTech LP Vena Cava Filter); Bard Peripheral Vascular Inc. (Denali Vena Cava Filter System); Cook Inc. (Cook Günther Tulip Vena Cava Filter); Cordis Corp. (Cordis OptEase Retrievable Vena Cava Filter/Cordis TrapEase Vena Cava Filter) and Volcano Corp. (Crux Vena Cava Filter System).

The five-year study will evaluate the overall safety and efficacy of filters placed by doctors and intends to enroll 2,100 patients at approximately 60 centers in the United States. There will be at least 300 patients enrolled for each participating manufacturer filter, and patients will be evaluated every six months post procedure up to 24 months or filter retrieval. Principal investigators are Matthew Johnson, M.D., FSIR, Indiana University School of Medicine, Indianapolis, Ind. and David Gillespie M.D., FACS, Southcoast Health System, Fall River, Mass.

Protocol development has been completed and an investigational device exemption (IDE) study with HIPAA (Health Insurance Portability and Accountability Act) compliance has been granted by the FDA. Members of the IVC Filter Study Group Foundation have been working with the contract research organization New England Research Institutes Inc. (NERI), and it’s expected that the first patients may enroll in spring 2015.

According to the U.S. Surgeon General, between 350,000 and 600,000 people each year in the United States are affected by blood clots and between 100,000 and 180,000 people die of pulmonary embolism each year. The FDA recommendations are that physicians remove the filters, which are designed to be retrievable, once the threat of pulmonary embolism has passed. The FDA warning said that all physicians were encouraged to consider the benefits and health risks of IVC filter removal for each patient.

Members of the IVC Filter Study Group Foundation board of directors (besides Kaufman and Lawrence) are SVS Executive Director Rebecca Maron, CAE (secretary); SIR Executive Director Susan Sedory Holzer, MA, CAE (treasurer); Peter Gloviczki, M.D., FACS (SVS representative); and Marshall Hicks, M.D., FSIR (SIR representative).

For more information: www.SIRweb.org, www.vascularweb.org

Related Content

Claret's FDA-cleared Sentinel Cerebral Embolic Protection System for TAVR will expand Boston Scientific's structural heart portfolio. It collects emboli knocked loose that would otherwise lodge in the brain and potentially cause a stroke.

Claret's FDA-cleared Sentinel Cerebral Embolic Protection System for TAVR will expand Boston Scientific's structural heart portfolio. It collects emboli knocked loose that would otherwise lodge in the brain and potentially cause a stroke. 

News | Embolic Protection Devices | July 20, 2018
July 20, 2018 — Boston Scientific Corp.
The Emboliner Embolic Protection Catheteris designed to capture debris released from the valve and vessel walls during transcatheter aortic valve replacement (TAVR) procedures.

The Emboliner Embolic Protection Catheter is designed to capture debris released from the valve and vessel walls during transcatheter aortic valve replacement (TAVR) procedures. It allows for the passage of other catheters during TAVR procedures. 

News | Embolic Protection Devices | June 07, 2018
June 7, 2018 — The first clinical cases have been completed where the Emboliner...
Sentinel Cerebral Protection System Reduces TAVR Strokes More Than 60 Percent
News | Embolic Protection Devices | May 08, 2018
May 8, 2018 — One-year results from the Sentinel Cerebral Protection System show it can reduce the incidence of...
Emboline Inc. Completes Funding for TAVR Embolic Protection Trial
News | Embolic Protection Devices | April 20, 2018
Emerging medical device company Emboline Inc. announced it has completed a Series B funding round totaling over $10...
Sentinel Cerebral Protection System Reaches 50-Center Adoption Milestone in U.S.
News | Embolic Protection Devices | February 19, 2018
Claret Medical announced that since U.S. Food and Drug Administration (FDA) clearance in June 2017, its Sentinel...
The Boston Scientific FilterWire EZ embolic protec filter system.

The Boston Scientific FilterWire EZ embolic protection system.

News | Embolic Protection Devices | October 31, 2017
October 31, 2017 — The VAMPIRE 3 study evaluated if the selective use of distal filter protection might decrease the
Claret Medical Closes $14.5 Million in Series C Financing for Sentinel Cerebral Protection System
News | Embolic Protection Devices | October 23, 2017
October 23, 2017 — Claret Medical announced that it has closed on a Series C financing of $14.5 million led by Lights
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices | September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Protembis Announces Successful First-in-Human Use of  ProtEmbo Cerebral Protection System in European Trial
News | Embolic Protection Devices | September 07, 2017
Protembis GmbH announced the first clinical applications of its ProtEmbo Cerebral Protection System to complement a...
PinnacleHealth First in Pennsylvania to Implant Sentinel Cerebral Protection System
News | Embolic Protection Devices | August 23, 2017
PinnacleHealth is the first hospital in Pennsylvania and one of the first 10 in the country to introduce new technology...
Overlay Init